These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1108 related articles for article (PubMed ID: 9308509)

  • 1. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV.
    Pinkerton SD; Holtgrave DR; Bloom FR
    AIDS; 1998 Jun; 12(9):1067-78. PubMed ID: 9662204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.
    Pinkerton SD; Martin JN; Roland ME; Katz MH; Coates TJ; Kahn JO
    Arch Intern Med; 2004 Jan; 164(1):46-54. PubMed ID: 14718321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
    Desai K; Sansom SL; Ackers ML; Stewart SR; Hall HI; Hu DJ; Sanders R; Scotton CR; Soorapanth S; Boily MC; Garnett GP; McElroy PD
    AIDS; 2008 Sep; 22(14):1829-39. PubMed ID: 18753932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of HIV post-exposure prophylaxis in France.
    Herida M; Larsen C; Lot F; Laporte A; Desenclos JC; Hamers FF
    AIDS; 2006 Aug; 20(13):1753-61. PubMed ID: 16931940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental cost-effectiveness of two zidovudine regimens to prevent perinatal HIV transmission in the United States.
    Pinkerton SD; Holtgrave DR; Layde PM
    Prev Med; 2000 Jan; 30(1):64-9. PubMed ID: 10642461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
    Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
    PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care.
    Mrus JM; Tsevat J
    Med Decis Making; 2004; 24(1):30-9. PubMed ID: 15005952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.
    Mauskopf J; Lacey L; Kempel A; Simpson K
    Am J Manag Care; 1998 Jul; 4(7):1004-12. PubMed ID: 10181990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing perinatal transmission of HIV--costs and effectiveness of a recommended intervention.
    Gorsky RD; Farnham PG; Straus WL; Caldwell B; Holtgrave DR; Simonds RJ; Rogers MF; Guinan ME
    Public Health Rep; 1996; 111(4):335-41. PubMed ID: 8711101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
    Marseille E; Saba J; Muyingo S; Kahn JG
    AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine.
    Biddle AK; Simpson KN
    Value Health; 2000; 3(3):186-201. PubMed ID: 16464183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S.
    Talbird SE; Brogan AJ; Winiarski AP
    Am J Prev Med; 2009 Nov; 37(5):381-8. PubMed ID: 19840692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New guidelines issued for occupational exposures.
    AIDS Policy Law; 1998 May; 13(10):10. PubMed ID: 11365445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The president's fiscal year 2007 initiative for human immunodeficiency virus counseling and testing expansion in the United States: a scenario analysis of its coverage, impact, and cost-effectiveness.
    Holtgrave DR
    J Public Health Manag Pract; 2007; 13(3):239-43. PubMed ID: 17435490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of HIV nonoccupational post-exposure prophylaxis in Australia.
    Guinot D; Ho MT; Poynten IM; McAllister J; Pierce A; Pell C; Grulich AE
    HIV Med; 2009 Apr; 10(4):199-208. PubMed ID: 19207598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of HIV Postexposure Prophylaxis in healthcare workers after occupational exposure: a Thai university hospital setting.
    Kiertiburanakul S; Wannaying B; Tonsuttakul S; Kehachindawat P; Apivanich S; Somsakul S; Malathum K
    J Med Assoc Thai; 2006 Jul; 89(7):974-8. PubMed ID: 16881429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.